Acrivon Therapeutics, Inc. (ACRV)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acrivon Therapeutics, Inc. (ACRV) trades at $1.33 with AI Score 45/100 (Weak). Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines. Market cap: 42M, Sector: Healthcare.
Last analyzed: Feb 8, 2026Acrivon Therapeutics, Inc. (ACRV) Healthcare & Pipeline Overview
Acrivon Therapeutics, Inc. leverages its innovative proteomics-based platform to develop targeted oncology therapies, positioning itself at the forefront of precision medicine with its lead candidate ACR-368 in Phase 2 trials across multiple tumor types.
Investment Thesis
Investors may want to evaluate Acrivon Therapeutics, Inc. due to its unique positioning in the oncology market, driven by its proprietary proteomics-based platform that enhances patient selection for therapies. With a market capitalization of $0.05 billion and a lead candidate, ACR-368, in a Phase 2 trial, the company is poised for significant value creation as it progresses towards potential commercialization. The growing demand for precision medicine in oncology, coupled with Acrivon's innovative approach to companion diagnostics, positions it well within a rapidly expanding market projected to reach $150 billion by 2025. Additionally, the company's focus on addressing unmet medical needs in difficult-to-treat cancers offers compelling growth catalysts, making ACRV a noteworthy investment opportunity.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.05 billion, indicating a significant growth potential as clinical trials progress.
- Lead candidate ACR-368 in a Phase 2 trial, targeting multiple tumor types including platinum-resistant ovarian cancer.
- Strong focus on precision medicine, aligning with industry trends towards personalized oncology treatments.
- No dividend yield, reflecting a reinvestment strategy aimed at advancing clinical trials and pipeline development.
- Beta of 1.76 suggests higher volatility, which may appeal to risk-tolerant investors seeking growth opportunities.
Competitors & Peers
Strengths
- Innovative proteomics-based patient identification platform.
- Strong pipeline with a lead candidate in Phase 2 trials.
- Experienced management team with expertise in oncology.
Weaknesses
- Clinical-stage company with no approved products yet.
- High dependency on successful trial outcomes for future growth.
- Limited financial resources relative to larger competitors.
Catalysts
- Upcoming: Results from the Phase 2 trial of ACR-368 expected in the second half of 2026.
- Ongoing: Development of preclinical pipeline programs targeting WEE1 and PKMYT1.
- Upcoming: Potential partnerships or collaborations to enhance R&D capabilities.
Risks
- Potential: Regulatory challenges in obtaining approval for ACR-368.
- Ongoing: Market competition from other oncology therapeutics and diagnostics.
- Potential: Financial risks associated with funding clinical trials and operations.
Growth Opportunities
- Growth opportunity 1: Acrivon's lead candidate, ACR-368, targets CHK1 and CHK2 pathways, which are critical in cancer cell cycle regulation. With the global cancer therapeutics market expected to reach $200 billion by 2025, ACR-368's potential approval could capture significant market share, especially in platinum-resistant ovarian and bladder cancers.
- Growth opportunity 2: The company's proprietary OncoSignature companion diagnostics enhance patient selection for ACR-368, increasing treatment efficacy and patient outcomes. As the demand for precision medicine grows, Acrivon's diagnostics could become essential tools in oncology, tapping into a diagnostics market projected to exceed $50 billion by 2025.
- Growth opportunity 3: Acrivon's preclinical pipeline, including programs targeting WEE1 and PKMYT1, addresses critical areas in DNA damage response. The growing focus on combination therapies in oncology could allow Acrivon to leverage these programs, potentially leading to partnerships or acquisitions by larger biopharmaceutical firms seeking innovative solutions.
- Growth opportunity 4: The increasing prevalence of cancer globally, with an estimated 19.3 million new cases in 2020, creates a substantial market for effective therapies. Acrivon's focus on difficult-to-treat cancers positions it to meet this urgent need, potentially leading to rapid adoption of its therapies upon approval.
- Growth opportunity 5: Collaborations with academic institutions and research organizations can enhance Acrivon's R&D capabilities. By leveraging external expertise and resources, Acrivon can accelerate its drug development timelines and expand its pipeline, increasing its competitive advantage in the fast-evolving oncology landscape.
Opportunities
- Growing demand for precision medicine in oncology.
- Potential partnerships with larger pharmaceutical companies.
- Expansion of the pipeline into additional oncology targets.
Threats
- Intense competition from established biopharmaceutical companies.
- Regulatory hurdles and uncertainties in drug approval processes.
- Market volatility impacting funding and investment opportunities.
Competitive Advantages
- Proprietary proteomics-based platform that enhances patient selection for therapies.
- Strong focus on precision medicine, aligning with industry trends and patient needs.
- Innovative companion diagnostics that differentiate Acrivon's offerings from competitors.
About ACRV
Acrivon Therapeutics, Inc., founded in 2018 and headquartered in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to advancing oncology medicines tailored to patients whose tumors are likely to respond to specific treatments. The company employs its proprietary Acrivon Predictive Precision Proteomics platform to develop OncoSignature companion diagnostics, which identify patients who would benefit from its drug candidates. This innovative approach not only enhances treatment efficacy but also aims to minimize unnecessary side effects for patients. Acrivon's lead clinical candidate, ACR-368, is a selective small molecule inhibitor targeting the CHK1 and CHK2 proteins, currently undergoing a potentially registrational Phase 2 trial that encompasses various tumor types, including platinum-resistant ovarian cancer, endometrial cancer, and bladder cancer. In addition to ACR-368, Acrivon is advancing its preclinical pipeline, which focuses on critical nodes in the DNA damage response and cell cycle regulation pathways, targeting proteins such as WEE1 and PKMYT1. With a team of 75 employees, Acrivon is at the cutting edge of biopharmaceutical innovation, aiming to transform cancer treatment through precision medicine.
What They Do
- Develop precision oncology medicines tailored to specific patient tumor profiles.
- Utilize a proprietary proteomics-based platform for patient responder identification.
- Create OncoSignature companion diagnostics to enhance treatment efficacy.
- Conduct clinical trials to evaluate the safety and effectiveness of drug candidates.
- Focus on difficult-to-treat cancers, including platinum-resistant ovarian and bladder cancers.
- Advance preclinical programs targeting key proteins in cancer pathways.
Business Model
- Revenue generation primarily through the development and potential commercialization of oncology therapeutics.
- Partnerships and collaborations with pharmaceutical companies for co-development and licensing opportunities.
- Potential future revenue from companion diagnostics associated with approved drug candidates.
Industry Context
The biotechnology industry, particularly in oncology, is experiencing rapid growth, driven by advancements in precision medicine and targeted therapies. The global oncology market is projected to grow at a CAGR of 7.5%, reaching approximately $150 billion by 2025. Acrivon Therapeutics, with its innovative proteomics-based platform, is well-positioned within this landscape, competing against peers such as ATYR, BMEA, and IMUX. The increasing focus on personalized medicine and the need for effective treatments for hard-to-treat cancers further enhance Acrivon's competitive positioning.
Key Customers
- Oncology patients requiring targeted therapies.
- Healthcare providers and oncologists seeking effective treatment options.
- Pharmaceutical companies interested in collaboration for drug development.
Financials
Chart & Info
Acrivon Therapeutics, Inc. (ACRV) stock price: $1.33 (-0.09, -6.34%)
Latest News
-
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga · May 1, 2025
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Oct 4, 2023
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACRV.
Price Targets
Wall Street price target analysis for ACRV.
MoonshotScore
What does this score mean?
The MoonshotScore rates ACRV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Common Questions About ACRV
What does Acrivon Therapeutics, Inc. Common Stock do?
Acrivon Therapeutics, Inc. focuses on developing precision oncology medicines by utilizing its proprietary proteomics-based platform. This innovative approach allows for the identification of patients whose tumors are likely to respond to specific therapies, enhancing treatment efficacy. The company is currently advancing its lead candidate, ACR-368, through clinical trials aimed at addressing unmet medical needs in oncology.
Is ACRV stock worth researching?
ACRV stock presents a notable research candidate due to its innovative approach in the oncology space and the potential for significant growth as its lead candidate, ACR-368, progresses through clinical trials. With a market cap of $0.05 billion and the oncology market projected to grow substantially, Acrivon's focus on precision medicine could yield strong returns for investors, particularly if trial results are favorable and lead to commercialization.
What are the main risks for ACRV?
Acrivon faces several risks, including regulatory challenges that could impede the approval of its lead candidate, ACR-368. Additionally, the company operates in a highly competitive oncology market, which could impact its market share and pricing power. Financial risks associated with funding ongoing clinical trials and operational costs also pose challenges, particularly for a clinical-stage company without approved products.
What are the key factors to evaluate for ACRV?
Acrivon Therapeutics, Inc. (ACRV) currently holds an AI score of 45/100, indicating low score. Key strength: Innovative proteomics-based patient identification platform.. Primary risk to monitor: Potential: Regulatory challenges in obtaining approval for ACR-368.. This is not financial advice.
How frequently does ACRV data refresh on this page?
ACRV prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ACRV's recent stock price performance?
Recent price movement in Acrivon Therapeutics, Inc. (ACRV) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative proteomics-based patient identification platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ACRV overvalued or undervalued right now?
Determining whether Acrivon Therapeutics, Inc. (ACRV) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ACRV?
Before investing in Acrivon Therapeutics, Inc. (ACRV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The analysis is based on current data and may be subject to change as new information becomes available.